THE BENEFITS
OF OUR PAYLOAD

Merlin is developing novel approaches to diseases where there are few effective therapies. Our lead asset, MER-101 is a first-in-class immuno-oncology therapy being developed solely by Merlin for adult solid cancers and pediatric sarcomas.